Department of Hematology & Hematopoietic Cell Transplantation
Hematologic cancers are those cancers that occur in cells of the immune system or in blood-forming tissues, including bone marrow. As a pioneer in advancing care for all hematologic cancers and related blood disorders, City of Hope's Department of Hematology & Hematopoietic Cell Transplantation leads the field as one of the largest and most successful transplant centers in the U.S.
The Center for International Blood and Marrow Transplant Research Center has ranked City of Hope as an “overperforming” transplant center, and we are the only U.S. transplant center with this recognition for over a decade. City of Hope's transplant program is accredited by the Foundation for the Accreditation of Cellular Therapy, the standard of excellence for blood and bone marrow transplant programs in the United States.
Led by Eileen Smith, M.D., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, our dedicated, multidisciplinary team combines innovative research discoveries with superior clinical treatments to improve outcomes for patients with:
- Leukemia (cancer of the blood cells) at the Gehr Family Center for Leukemia Research
- Lymphoma (cancer of the lymphatic cells) at the Toni Stephenson Lymphoma Center
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Myeloma (cancer of plasma cells) at the Judy and Bernard Briskin Center for Multiple Myeloma Research
- Myelodysplastic syndrome (blood abnormalities that can be life-threatening or lead to cancer)
- Other hematologic disorders
Hematologic Malignancies Research Institute
A world leader in the treatment of blood cancers, City of Hope launched an institute to specifically focus on treating people with serious blood and bone marrow diseases. Through this institute, laboratory and physician investigators are expanding their work and developing new therapies and possible cures for leukemia, lymphoma and multiple myeloma.